370 related articles for article (PubMed ID: 30267354)
21. Giant prolactinomas presenting as skull base tumors.
Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
[TBL] [Abstract][Full Text] [Related]
22. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
23. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new.
Chanson P; Maiter D
Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373
[TBL] [Abstract][Full Text] [Related]
24. Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study.
Himonakos C; Burman P; Borg H; Dahlqvist P; Engström BE; Ekman B; Emilsson L; Olsson DS; Ragnarsson O; Wahlberg J; Åkerman AK; Höybye C; Berinder K
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1506-e1514. PubMed ID: 37403202
[TBL] [Abstract][Full Text] [Related]
25. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
26. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
27. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
29. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
30. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
[TBL] [Abstract][Full Text] [Related]
31. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas.
Ozkaya HM; Sahin S; Korkmaz OP; Durcan E; Sahin HR; Celik E; Poyraz BC; Kadioglu P
Growth Horm IGF Res; 2020 Dec; 55():101356. PubMed ID: 33010581
[TBL] [Abstract][Full Text] [Related]
32. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
[TBL] [Abstract][Full Text] [Related]
33. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
34. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
35. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
[TBL] [Abstract][Full Text] [Related]
36. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
38. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor β1 is not a reliable biomarker for valvular fibrosis but could be a potential serum marker for invasiveness of prolactinomas (pilot study).
Elenkova A; Atanassova I; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
Eur J Endocrinol; 2013 Sep; 169(3):299-306. PubMed ID: 23801826
[TBL] [Abstract][Full Text] [Related]
40. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
